Veritas In Silico Inc.
130A・Growth Market・Pharmaceuticals
Veritas In Silico Inc.130A
Recent Disclosures
| Date | Type | Title |
|---|---|---|
| 2026-07-13 | Other | Personnel Changes in Executive Officer |
| 2026-07-13 | Other | 人事異動（執行役員）のお知らせ |
| 2026-05-18 | Other | Pre-Consultation Meeting with Pharmaceuticals and Medical Devices Agency (PMDA) towards the Commercialization of the Drug Delivery System "Perfusio" |
| 2026-05-18 | Other | ドラッグデリバリーシステム「Perfusio」の事業化に向けた医薬品医療機器総合機構(PMDA)との医療機器・体外診断用医薬品 対面助言準備面談実施のお知らせ |
| 2026-05-11 | Other | Notice of Extraordinary Loss Due to Impairment Accounting |
| 2026-05-11 | Other | 2026年12月期 第１四半期 決算説明資料 |
| 2026-05-11 | Other | SpiroChem and Veritas In Silico entered into Joint Research Agreement to Initiate the Discovery of Next Generation mRNA Binding Chemical Matter |
| 2026-05-11 | Other | Non-consolidated Financial Results for the Three Months Ended March 31,2026 [Under Japanese GAAP] |
| 2026-05-11 | Earnings Report | 2026年12月期 第１四半期決算短信〔日本基準〕(非連結) |
| 2026-05-11 | Other | SpiroChem と Veritas In Silico、mRNA標的化合物の共同探索研究契約締結のお知らせ |